FDA to hold 'off-label' drug meeting
This article was originally published in Scrip
Executive Summary
For those eager to gain insight into what the FDA's latest thinking is on whether it plans to loosen rules that restrict biopharmaceutical makers from discussing off-label uses of their drugs, watch the Federal Register – the place where the US government informs the public of federal actions, including plans for public meetings.